CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.
Earlier this month, CRISPR Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, ...
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
Summit Therapeutics has generated plenty of buzz in the biotech industry over the past two years. That's because the ...
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...
Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...
CRISPR-Cas9 genome editing enzyme. [Artur Plawgo / iStock / Getty Images Plus] We need a patient-first approach for any variant in any patient, whomever, wherever they are. Each and every patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback